NovoCure

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NovoCure and other ETFs, options, and stocks.

About NVCR

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. 

CEO
Frank Leonard
CEOFrank Leonard
Employees
1,605
Employees1,605
Headquarters
St. Helier, Jersey
HeadquartersSt. Helier, Jersey
Founded
2000
Founded2000
Employees
1,605
Employees1,605

NVCR Key Statistics

Market cap
2.07B
Market cap2.07B
Price-Earnings ratio
-11.66
Price-Earnings ratio-11.66
Dividend yield
Dividend yield
Average volume
2.53M
Average volume2.53M
High today
$17.86
High today$17.86
Low today
$17.67
Low today$17.67
Open price
$16.90
Open price$16.90
Volume
733.00
Volume733.00
52 Week high
$20.06
52 Week high$20.06
52 Week low
$9.82
52 Week low$9.82

Stock Snapshot

As of today, NovoCure(NVCR) shares are valued at $17.70. The company's market cap stands at 2.07B, with a P/E ratio of -11.66.

On 2026-05-11, NovoCure(NVCR) stock moved within a range of $17.67 to $17.86. With shares now at $17.70, the stock is trading +0.2% above its intraday low and -0.9% below the session's peak.

Trading volume for NovoCure(NVCR) stock has reached 733, versus its average volume of 2.53M.

The stock's 52-week range extends from a low of $9.82 to a high of $20.06.

The stock's 52-week range extends from a low of $9.82 to a high of $20.06.

NVCR News

Simply Wall St 2d
A Look At NovoCure Valuation After Raised 2026 Revenue Guidance And Q1 Beat

NovoCure (NVCR) has drawn fresh attention after reporting first quarter 2026 revenue that exceeded expectations and raising its full-year revenue outlook to a r...

A Look At NovoCure Valuation After Raised 2026 Revenue Guidance And Q1 Beat
Simply Wall St 7d
Why NovoCure Is Up 33.2% After FDA Clears Optune Pax And Guidance Ticks Higher

In the first quarter of 2026, NovoCure reported net revenues of US$174.06 million, up from US$154.99 million a year earlier, while its net loss widened to US$71...

Why NovoCure Is Up 33.2% After FDA Clears Optune Pax And Guidance Ticks Higher

Analyst ratings

75%

of 8 ratings
Buy
75%
Hold
25%
Sell
0%

People also own

Based on the portfolios of people who own NVCR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.